Subscribe
shutterstock_771074422_andrey_kuzmin
Andrey Kuzmin / Shutterstock.com
1 July 2019Big Pharma

SPC generics waiver comes into force

The controversial supplementary protection certificate (SPC) manufacturing waiver has come into force today, July 1.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
AIPPI World Congress 2019: SPC and PTEs around the world
17 September 2019   This week at the AIPPI World Congress 2019, counsel discussed how supplementary protection certificates and patent term extension regulations differ across jurisdictions.
Generics
EU adopts SPC manufacturing waiver
16 May 2019   The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
AIPPI World Congress 2019: SPC and PTEs around the world
17 September 2019   This week at the AIPPI World Congress 2019, counsel discussed how supplementary protection certificates and patent term extension regulations differ across jurisdictions.
Generics
EU adopts SPC manufacturing waiver
16 May 2019   The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
AIPPI World Congress 2019: SPC and PTEs around the world
17 September 2019   This week at the AIPPI World Congress 2019, counsel discussed how supplementary protection certificates and patent term extension regulations differ across jurisdictions.
Generics
EU adopts SPC manufacturing waiver
16 May 2019   The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims